# Definium Therapeutics, Inc.: financial statements, quarterly

DFTX · Nasdaq · CIK 1813814 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dftx.md) · [Financials](/companies/dftx/financials.md) · [Filings](/companies/dftx/filings.md) · [Insiders](/companies/dftx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dftx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [13.2](/filings/0000950170-24-123391.md) | [11.5 d](/filings/0000950170-25-034176.md) | [11.7](/filings/0000950170-25-066387.md) | [14.6](/filings/0000950170-25-100925.md) | [17.2](/filings/0001193125-25-269596.md) | [21.8 d](/filings/0001193125-26-076742.md) | [23.4](/filings/0001193125-26-211989.md) | [29.8](/filings/0001193125-26-338066.md) | [31.0](/filings/0001193125-25-269596.md) | [33.5 d](/filings/0001193125-26-076742.md) | [41.5](/filings/0001193125-26-211989.md) | [48.7](/filings/0001193125-26-338066.md) |
| Operating income | $m | [(21.6)](/filings/0000950170-24-123391.md) | [(22.2) d](/filings/0000950170-25-034176.md) | [(22.2)](/filings/0000950170-25-066387.md) | [(24.5)](/filings/0000950170-25-100925.md) | [(24.8)](/filings/0001193125-25-269596.md) | [(32.5) d](/filings/0001193125-26-076742.md) | [(32.2)](/filings/0001193125-26-211989.md) | [(40.9)](/filings/0001193125-26-338066.md) | [(45.7)](/filings/0001193125-25-269596.md) | [(47.6) d](/filings/0001193125-26-076742.md) | [(59.2)](/filings/0001193125-26-211989.md) | [(75.1)](/filings/0001193125-26-338066.md) |
| Interest expense | $m | [0.3](/filings/0000950170-24-123391.md) | [0.4 d](/filings/0000950170-25-034176.md) | [0.4](/filings/0000950170-25-066387.md) | [0.5](/filings/0000950170-25-100925.md) | [0.7](/filings/0001193125-25-269596.md) | [0.7 d](/filings/0001193125-26-076742.md) | [0.6](/filings/0001193125-26-211989.md) | [2.3](/filings/0001193125-26-338066.md) | [1.3](/filings/0001193125-25-269596.md) | [1.3 d](/filings/0001193125-26-076742.md) | [1.2](/filings/0001193125-26-211989.md) | [1.2](/filings/0001193125-26-338066.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(17.9)](/filings/0000950170-24-123391.md) | [(23.9) d](/filings/0000950170-25-034176.md) | [(54.4)](/filings/0000950170-25-066387.md) | [(5.9)](/filings/0000950170-25-100925.md) | [(13.7)](/filings/0001193125-25-269596.md) | [(34.7) d](/filings/0001193125-26-076742.md) | [(23.3)](/filings/0001193125-26-211989.md) | [(42.7)](/filings/0001193125-26-338066.md) | [(67.3)](/filings/0001193125-25-269596.md) | [(50.4) d](/filings/0001193125-26-076742.md) | [(77.1)](/filings/0001193125-26-211989.md) | [(159)](/filings/0001193125-26-338066.md) |
| Diluted EPS | $ per share | [(0.45)](/filings/0000950170-24-123391.md) | not reported | [(1.14)](/filings/0000950170-25-066387.md) | [(0.26)](/filings/0000950170-25-100925.md) | [(0.27)](/filings/0001193125-25-269596.md) | not reported | [(0.35)](/filings/0001193125-26-211989.md) | [(0.50)](/filings/0001193125-26-338066.md) | [(0.78)](/filings/0001193125-25-269596.md) | not reported | [(0.71)](/filings/0001193125-26-211989.md) | [(1.44)](/filings/0001193125-26-338066.md) |
| Basic EPS | $ per share | [(0.45)](/filings/0000950170-24-123391.md) | not reported | [(1.14)](/filings/0000950170-25-066387.md) | [(0.08)](/filings/0000950170-25-100925.md) | [(0.18)](/filings/0001193125-25-269596.md) | not reported | [(0.27)](/filings/0001193125-26-211989.md) | [(0.50)](/filings/0001193125-26-338066.md) | [(0.78)](/filings/0001193125-25-269596.md) | not reported | [(0.71)](/filings/0001193125-26-211989.md) | [(1.44)](/filings/0001193125-26-338066.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [118](/filings/0000950170-23-058248.md) | [99.7](/filings/0000950170-25-034176.md) | [252](/filings/0000950170-24-055681.md) | [243](/filings/0000950170-24-095753.md) | [295](/filings/0000950170-24-123391.md) | [274](/filings/0001193125-26-076742.md) | [82.9](/filings/0000950170-25-066387.md) | [33.4](/filings/0000950170-25-100925.md) | [20.0](/filings/0001193125-25-269596.md) | [258](/filings/0001193125-26-338066.md) | [263](/filings/0001193125-26-211989.md) | [655](/filings/0001193125-26-338066.md) |
| Current assets | $m | [120](/filings/0000950170-23-058248.md) | [104](/filings/0000950170-25-034176.md) | [255](/filings/0000950170-24-055681.md) | [248](/filings/0000950170-24-095753.md) | [299](/filings/0000950170-24-123391.md) | [282](/filings/0001193125-26-076742.md) | [222](/filings/0000950170-25-066387.md) | [189](/filings/0000950170-25-100925.md) | [216](/filings/0001193125-25-269596.md) | [419](/filings/0001193125-26-338066.md) | [381](/filings/0001193125-26-211989.md) | [1,092](/filings/0001193125-26-338066.md) |
| Total assets | $m | [142](/filings/0000950170-23-058248.md) | [125](/filings/0000950170-25-034176.md) | [276](/filings/0000950170-24-055681.md) | [268](/filings/0000950170-24-095753.md) | [320](/filings/0000950170-24-123391.md) | [302](/filings/0001193125-26-076742.md) | [275](/filings/0000950170-25-066387.md) | [265](/filings/0000950170-25-100925.md) | [237](/filings/0001193125-25-269596.md) | [440](/filings/0001193125-26-338066.md) | [401](/filings/0001193125-26-211989.md) | [1,113](/filings/0001193125-26-338066.md) |
| Current liabilities | $m | [31.2](/filings/0000950170-23-058248.md) | [32.2](/filings/0000950170-25-034176.md) | [65.3](/filings/0000950170-24-055681.md) | [41.8](/filings/0000950170-24-095753.md) | [33.3](/filings/0000950170-24-123391.md) | [38.8](/filings/0001193125-26-076742.md) | [30.5](/filings/0000950170-25-066387.md) | [38.0](/filings/0000950170-25-100925.md) | [65.4](/filings/0001193125-25-269596.md) | [66.7](/filings/0001193125-26-338066.md) | [81.1](/filings/0001193125-26-211989.md) | [157](/filings/0001193125-26-338066.md) |
| Total liabilities | $m | [45.6](/filings/0000950170-23-058248.md) | [46.4](/filings/0000950170-25-034176.md) | [79.5](/filings/0000950170-24-055681.md) | [66.1](/filings/0000950170-24-095753.md) | [57.6](/filings/0000950170-24-123391.md) | [60.7](/filings/0001193125-26-076742.md) | [52.5](/filings/0000950170-25-066387.md) | [79.7](/filings/0000950170-25-100925.md) | [106](/filings/0001193125-25-269596.md) | [108](/filings/0001193125-26-338066.md) | [122](/filings/0001193125-26-211989.md) | [194](/filings/0001193125-26-338066.md) |
| Long-term debt | $m | [14.1](/filings/0000950170-23-058248.md) | [14.1](/filings/0000950170-24-021656.md) | [14.2](/filings/0000950170-24-055681.md) | [24.3](/filings/0000950170-24-095753.md) | [24.3](/filings/0000950170-24-123391.md) | [21.9](/filings/0000950170-25-034176.md) | [22.0](/filings/0000950170-25-066387.md) | [41.2](/filings/0000950170-25-100925.md) | [40.4](/filings/0001193125-25-269596.md) | [40.6](/filings/0001193125-26-076742.md) | [40.8](/filings/0001193125-26-211989.md) | [36.5](/filings/0001193125-26-338066.md) |
| Shareholders' equity | $m | [96.0](/filings/0000950170-24-123391.md) | [78.1](/filings/0001193125-26-076742.md) | [196](/filings/0001193125-25-269596.md) | [202](/filings/0001193125-25-269596.md) | [262](/filings/0001193125-25-269596.md) | [241](/filings/0001193125-26-338066.md) | [223](/filings/0001193125-26-338066.md) | [185](/filings/0001193125-26-338066.md) | [131](/filings/0001193125-25-269596.md) | [332](/filings/0001193125-26-338066.md) | [279](/filings/0001193125-26-338066.md) | [919](/filings/0001193125-26-338066.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.6) d](/filings/0000950170-24-123391.md) | [(20.6) d](/filings/0000950170-25-034176.md) | [(16.6)](/filings/0000950170-25-066387.md) | [(20.0) d](/filings/0000950170-25-100925.md) | [(17.2) d](/filings/0001193125-25-269596.md) | [(25.4) d](/filings/0001193125-26-076742.md) | [(29.4)](/filings/0001193125-26-211989.md) | [(29.6) d](/filings/0001193125-26-338066.md) | [(29.6) d](/filings/0001193125-25-269596.md) | [(43.0) d](/filings/0001193125-26-076742.md) | [(42.6)](/filings/0001193125-26-211989.md) | [(52.8) d](/filings/0001193125-26-338066.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.3](/filings/0000950170-23-058248.md) | [38.1](/filings/0000950170-24-055681.md) | [38.6](/filings/0000950170-24-095753.md) | [39.7](/filings/0000950170-24-123391.md) | [47.9](/filings/0000950170-25-066387.md) | [75.3](/filings/0000950170-25-100925.md) | [80.2](/filings/0001193125-25-269596.md) | [87.1](/filings/0001193125-26-211989.md) | [85.3](/filings/0001193125-26-338066.md) | [85.9](/filings/0001193125-25-269596.md) | [109](/filings/0001193125-26-211989.md) | [111](/filings/0001193125-26-338066.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 134,366,950 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338066.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.